These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 7503483)

  • 61. Emerging therapies for hepatitis C virus (HCV) infection: the importance of HCV genotype.
    McCaughan GW; Strasser SI
    Aust N Z J Med; 2000 Dec; 30(6):644-6. PubMed ID: 11198570
    [No Abstract]   [Full Text] [Related]  

  • 62. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy.
    Shindo M; Arai K; Sokawa Y; Okuno T
    Ann Intern Med; 1995 Apr; 122(8):586-91. PubMed ID: 7887552
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus.
    Jenkins ET; Jensen DM
    Infect Dis Clin North Am; 2012 Dec; 26(4):879-91. PubMed ID: 23083821
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.
    Herrmann E; Lee JH; Marinos G; Modi M; Zeuzem S
    Hepatology; 2003 Jun; 37(6):1351-8. PubMed ID: 12774014
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Is it now the time to update treatment protocols for lymphomas with new anti-virus systems?
    Luppi M; Barozzi P; Potenza L; Riva G; Morselli M; Torelli G
    Leukemia; 2004 Oct; 18(10):1572-5. PubMed ID: 15284857
    [No Abstract]   [Full Text] [Related]  

  • 66. Hepatitis C virus genotypes in serum and liver of children with chronic hepatitis C.
    Castillo I; Bartolomé J; Ruiz-Moreno M; Sanchez V; Navas S; Carreño V
    Pediatr Res; 1995 Oct; 38(4):618-20. PubMed ID: 8559619
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Therapeutic response to alpha-interferon in chronic alcoholics with viral hepatitis C].
    Nikitin IG; Kuznetsov SL; Liuliaeva OD; Storozhakov GI; Kisliakov VA; Uskov IuI
    Klin Med (Mosk); 1998; 76(8):33-5. PubMed ID: 9770965
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hepatitis C virus RNA and anti-N14 antibody levels during interferon alpha therapy for chronic hepatitis C.
    Oketani M; Tanaka K; Sho Y; Maeda E; Miyazaki H; Arima T
    Intern Med; 1994 Oct; 33(10):588-92. PubMed ID: 7530068
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A change of peginterferon may permit continuation of antiviral therapy in hepatitis C virus-infected patients with interstitial pneumonitis.
    Shimada M; Yoshida S; Kornek M; Kim SJ; Schuppan D
    Liver Int; 2010 Nov; 30(10):1552-4. PubMed ID: 20557455
    [No Abstract]   [Full Text] [Related]  

  • 70. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.
    Aghemo A; Rumi MG; Colombo M
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):925-35. PubMed ID: 19803700
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong.
    Yuen MF; Lai CL
    Intervirology; 2006; 49(1-2):96-8. PubMed ID: 16166796
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
    Yu ML; Dai CY; Huang JF; Chuang WL
    Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
    [No Abstract]   [Full Text] [Related]  

  • 74. Current and future therapies for hepatitis C virus infection.
    Liang TJ; Ghany MG
    N Engl J Med; 2013 May; 368(20):1907-17. PubMed ID: 23675659
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Histopathology and detection of hepatitis C virus in liver.
    Scheuer PJ; Krawczynski K; Dhillon AP
    Springer Semin Immunopathol; 1997; 19(1):27-45. PubMed ID: 9266629
    [No Abstract]   [Full Text] [Related]  

  • 76. Interferon therapy for chronic hepatitis C.
    Davis GL
    Baillieres Clin Gastroenterol; 1996 Jul; 10(2):289-98. PubMed ID: 8864035
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Eradication of hepatitis C virus RNA after alpha-interferon therapy.
    Romeo R; Pol S; Berthelot P; Brechot C
    Ann Intern Med; 1994 Aug; 121(4):276-7. PubMed ID: 8037409
    [No Abstract]   [Full Text] [Related]  

  • 78. [The pediatrician and hepatitis C virus].
    Bost-Bru C
    Arch Pediatr; 1999 Oct; 6(10):1122-5. PubMed ID: 10544791
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon.
    Rubbia-Brandt L; Giostra E; Mentha G; Quadri R; Negro F
    J Hepatol; 2001 Aug; 35(2):307. PubMed ID: 11580157
    [No Abstract]   [Full Text] [Related]  

  • 80. Hepatitis.
    Marsano LS
    Prim Care; 2003 Mar; 30(1):81-107. PubMed ID: 12825251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.